Oncotelic and Sapu Bioscience Unveil Groundbreaking Research
Breakthrough Review Defines the Next Frontier in Precision Nanomedicine
Oncotelic Therapeutics Inc. (OTLC) and Sapu Bioscience have recently achieved a significant milestone with their latest publication in the International Journal of Molecular Sciences. Their article, titled “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,”, serves as a pivotal review focusing on the transformative potential of nanoparticles specifically in the 5–15 nm size range.
This groundbreaking review is authored by industry experts including Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, making waves in the realm of nanomedicine.
Understanding the New Paradigm in Nanodrugs
This research emphasizes that while conventional clinical nanodrugs usually use larger carriers ranging from 50 nm to 200 nm, emerging data suggest that nanoparticles smaller than 15 nm present unique biological behaviors. These ultra-small nanoparticles are emerging as a revolutionary approach to drug delivery.
Advantages of Sub-15 nm Nanoparticles
The review reveals multiple benefits associated with these diminutive systems:
- Deeper Tissue and Tumor Penetration: They can reach difficult areas in tissues and tumors that are inaccessible to larger carriers.
- Reduced Organ Toxicity: The reduced accumulation in the reticuloendothelial system coupled with swift renal clearance reduces long-term toxicity.
- Enhanced Diffusion: Their smaller size allows for better diffusion across biological barriers, including the challenging blood-brain barrier.
- Quantum-Scale Surface Properties: These properties support multifunctional applications in imaging and therapy.
This strategic focus on sub-15 nm nanoparticles represents a novel pharmacological approach that aims to optimize delivery methods, enhancing both therapeutic effects and safety across various treatments.
Revolutionizing Cancer Therapy
Saran Saund, CBO of Oncotelic, highlights, “Sub-15 nm nanoparticles are not merely smaller versions of existing nanomedicines; they represent a new class of therapeutic agents entirely.” This innovation could lead to the development of more effective and selective cancer treatments that are capable of overcoming biological barriers.
Insights from Leadership
Dr. Tapas De, Director of NanoFormulation at Oncotelic and the article’s lead author, stated, “Our analysis shows that this ultrasmall size range achieves an optimal balance between deep tumor diffusion and systemic safety, similar to the efficacy with which natural biomolecules operate.”
Implications for Sapu's Nanomedicine Pipeline
The implications of these findings are significant, particularly for Sapu’s Deciparticle™ platform, which includes Sapu-003. This innovative intravenous formulation of everolimus is gearing up for its initial human trials.
Saund emphasized, “The publication of this comprehensive review substantiates our Deciparticle™ technology's foundation. The capability to manufacture nanoparticles under 15 nm will be crucial for venturing into new therapeutic areas ranging from cancer treatment to neurological and immune disorders.”
About Oncotelic Therapeutics
Oncotelic, originally established as OXiGENE, Inc. in the late 1980s, has undergone significant transformation into a focused biotechnology company. Their mission is deeply rooted in revolutionizing treatment options for cancer, particularly addressing rare pediatric disorders. They aim to achieve marked improvements in survival rates for patients afflicted by challenging conditions, leveraging their extensive knowledge in oncology. Moreover, the recent acquisition of PointR Data Inc. is set to enhance their capabilities in artificial intelligence-driven biotechnology, alongside their advancements in delivering novel therapies.
Frequently Asked Questions
What is the focus of the recent publication by Oncotelic and Sapu Bioscience?
The publication focuses on the therapeutic potential of sub-15 nm nanoparticles for drug delivery, exploring their distinct biological behaviors compared to larger nanoparticle systems.
Why are sub-15 nm nanoparticles significant?
These nanoparticles demonstrate unique properties such as deeper tissue penetration, reduced toxicity, and enhanced diffusion across biological barriers, which could lead to more effective cancer treatments.
How did the authors conduct their research?
The authors performed a systematic review of existing literature to analyze the benefits and applications of nanoparticles within the 5–15 nm size range in various therapeutic settings.
What will be the next steps for Sapu Bioscience?
Sapu Bioscience plans to advance its Deciparticle™ platform into clinical testing, beginning with Sapu-003, an intravenous nanomedicine currently preparing for patient trials.
Does Oncotelic have future plans for other therapeutic areas?
Yes, Oncotelic is exploring multiple therapeutic areas, including oncology and treatments for neurological and immune disorders, utilizing their nanoparticle technology.
